GlassScriptPhysician profile
Prachi Dalal
NPI 1134813900
$2,133.58
in general payments reported to CMS, 2019-2025
28 companies · $923 in 2025
The $923 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $243 · 2024: $968 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,088 · Education: $45.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,088.48 |
| Education | $45.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $358.28 | 2023-2025 | Briviact, Rystiggo, Fintepla |
| Lundbeck LLC | $235.18 | 2023-2025 | Vyepti |
| Abbvie INC. | $182.86 | 2023-2025 | |
| Harmony Biosciences LLC | $146.25 | 2023-2025 | Wakix |
| Alexion Pharmaceuticals, INC. | $145.84 | 2023-2025 | Ultomiris |
| Sk Life Science, INC. | $122.86 | 2024-2025 | |
| Catalyst Pharmaceuticals, INC. | $121.97 | 2024-2025 | |
| Eisai INC. | $86.96 | 2024-2025 | |
| Lilly USA, LLC | $79.32 | 2025 | Zepbound |
| Biogen, INC. | $57.78 | 2025 | Vumerity, Tysabri |
| Pfizer INC. | $57.46 | 2023-2024 | |
| Livanova USA, INC. | $53.64 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Argenx US, INC. | $50.64 | 2024-2025 | Vyvgart Hytrulo |
| Octapharma USA, INC. | $48.90 | 2025 | Panzyga |
| Jazz Pharmaceuticals INC. | $38.89 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $37.79 | 2024 | Austedo Xr |
| Merz Pharmaceuticals, LLC | $36.45 | 2025 | Xeomin, Inbrija |
| Acadia Pharmaceuticals INC | $33.31 | 2025 | Nuplazid |
| Neurelis, INC. | $31.59 | 2024 | Valtoco |
| Tanabe Pharma America, INC. | $28.71 | 2025 | Radicava |
| Otsuka America Pharmaceutical, INC. | $27.38 | 2025 | Rexulti |
| Grifols USA, LLC | $25.18 | 2025 | Gamunex-C |
| Genentech USA, INC. | $25.12 | 2024 | Ocrevus Zunovo, Ocrevus |
| Avadel Cns Pharmaceuticals, LLC | $24.53 | 2024 | Lumryz |
| Xeris Pharmaceuticals, INC. | $22.19 | 2025 | Keveyis |
| Csl Behring | $20.21 | 2025 | Hizentra |
| Ani Pharmaceuticals, INC. | $18.77 | 2025 | Purified Cortrophin Gel |
| Acorda Therapeutics, INC | $15.52 | 2024 | Ampyra, Inbrija |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prachi Dalal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.